|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM311973655 |
| 003 |
DE-627 |
| 005 |
20231225143415.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2020 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2020.108521
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1039.xml
|
| 035 |
|
|
|a (DE-627)NLM311973655
|
| 035 |
|
|
|a (NLM)32619647
|
| 035 |
|
|
|a (PII)S1521-6616(20)30353-3
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Delgado Silva, Joana
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Activated double-negative T cells (CD3+CD4-CD8-HLA-DR+) define response to renal denervation for resistant hypertension
|
| 264 |
|
1 |
|c 2020
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 17.05.2021
|
| 500 |
|
|
|a Date Revised 17.05.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2020 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a PURPOSE: To explore the cellular immune response of patients with resistant hypertension treated with renal denervation (RDN)
|
| 520 |
|
|
|a METHODS AND RESULTS: Twenty-three patients were included and blood samples were obtained in six timings, pre and post procedure. Response was evaluated at six-months and one year and was observed in 69.6% and 82.6% of patients, respectively. Absolute values of HLA-DR+ double negative (DN) T cells were significantly lower in the group of 'responders' at one year, and interaction between the timings were found in three T cell subsets (T CD4, T CD8 and naïve T CD8 cells), with the 'responders' tending to present with lower absolute values and little inter-timing variation
|
| 520 |
|
|
|a CONCLUSIONS: 'Responders' significantly present with lower absolute values of activated DN T cells and have lower and more stable values of total T CD8+, CD4+, and naïve T CD8+ cells. These cell types may be able to predict response to RDN
|
| 650 |
|
4 |
|a Clinical Trial
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Biomarker
|
| 650 |
|
4 |
|a Double-negative T cells
|
| 650 |
|
4 |
|a Hypertension
|
| 650 |
|
4 |
|a Immune system
|
| 650 |
|
4 |
|a Inflammation
|
| 650 |
|
4 |
|a Renal denervation
|
| 650 |
|
7 |
|a Cytokines
|2 NLM
|
| 700 |
1 |
|
|a Almeida, Jani-Sofia
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Rodrigues-Santos, Paulo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Santos Rosa, Manuel
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gonçalves, Lino
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 218(2020) vom: 10. Sept., Seite 108521
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:218
|g year:2020
|g day:10
|g month:09
|g pages:108521
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2020.108521
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 218
|j 2020
|b 10
|c 09
|h 108521
|